Chinese Journal of Pharmacovigilance ›› 2020, Vol. 17 ›› Issue (8): 502-507.
DOI: 10.19803/j.1672-8629.2020.08.11
Previous Articles Next Articles
HE Guilin1, ZUO Li2, CHEN Jiayin1, ZHOU Xueqin1, Wang Qian2,*
Received:
2020-07-31
Revised:
2020-07-31
Online:
2020-08-15
Published:
2020-07-31
Supported by:
CLC Number:
HE Guilin, ZUO Li, CHEN Jiayin, ZHOU Xueqin, Wang Qian. Adverse Drug Reactions/Events Induced by ACEI/ARB[J]. Chinese Journal of Pharmacovigilance, 2020, 17(8): 502-507.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.zgywjj.com/EN/10.19803/j.1672-8629.2020.08.11
[1] 奚倩兰, 刘凯, 陈晓平. 《高血压合理用药指南》解读之肾素-血管紧张素-醛固酮系统抑制剂治疗高血压并发症[J]. 中国循证医学杂志, 2018, 18(1):2-7. [2] 王春雪. 肾素血管紧张素系统阻断剂与脑卒中[J]. 中华高血压杂志, 2017, 25(4):322-325. [3] Moon JY.Recent Update of Renin-angiotensin-aldosterone System in the Pathogenesis of Hypertension[J]. Electrolyte Blood Press..2013, 11(2):41-45. [4] Palevsky PM, Zhang JH, Seliger SL, et al.Incidence, Severity, and Outcomes of AKI Associated with Dual Renin-Angiotensin System Blockade[J]. Clin J Am Soc Nephrol, 2016, 11(11): 1944-1953. [5] De Boer IH, Bangalore S, Benetos A, et al.Diabetes and Hypertension:A Position Statement by the American Diabetes Association[J].Diabetes Care, 2017, 40(9):1273-1284. [6] 国家食品药品监督管理总局药品评价中心. 药品不良反应报告和监测工作手册[EB/OL]. (2013-04-26)[2019-10-08]. http://www.cdr-adr.org.cal/was5/wed/search. [7] 任晓蕾,杨乐,李玉珍. ACEI类药物致不良反应分析及临床合理用药[J]. 中国医院用药评价与分析, 2010, 10(09):837-839. [8] 徐朝飞. 应用血管紧张素转换酶抑制剂不良反应的特征分析[J].中国循证心血管医学杂志, 2017, 9(8):969-971. [9] 杨鹏. 对36例ACEI类药物所致不良反应的综合分析[J]. 当代医药论丛, 2014, 12(13):174-176. [10] Bangalore S, Kumar S, Messerli FH.Angiotensin-converting enzyme inhibitor associated cough: deceptive information from the Physicians'Desk Reference[J]. Am J Med, 2010, 123(11):1016-1030. [11] Matchar DB, McCrory DC, Orlando LA, et al. Systematic review:comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension[J]. Ann Intern Med, 2008, 148(1):16-29. [12] 夏益兰. 常用三类抗高血压药物的不良反应监测分析[J]. 临床医药文献电子杂志, 2017, 4(65):12823-12824. [13] 李磊. 112例抗高血压药品不良反应分析[J]. 中国药物警戒,2012, 9(8):485-486. [14] ONTARGET Investigators, Yusuf S, Teo KK, et al.Telmisartan, ramipril, or both in patients at high risk for vascular events[J]. N Engl J Med, 2008, 358(15):1547-1559. [15] 林海龙,王旭开,王其梗,等. 血管紧张素转换酶抑制剂与血管紧张素受体拮抗剂治疗高血压:有无优劣之分? 如何选择?[J].中华高血压杂志, 2017, 25(9):811-817. [16] 张俊芳, 王映辉. ACEI及AT_1R拮抗剂的不良反应和临床处理[J]. 中国药师, 2003, 6(5):309-311. |
[1] | SUN Qiyue, ZHAO Ronghua, GUO Shanshan, BAO Lei, GENG Zihan, LI Shuran, XU Yingli, ZHANG Jingsheng, CUI Xiaolan, SUN Jing. Multiple pharmacological effects of Lingyang Ganmao Oral Liquid [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 127-131. |
[2] | ZHAO Ronghua, SUN Jing, BAO Lei, GENG Zihan, TAO Xiali, ZHANG Jingsheng, PANG Bo, XU Yingli, CAO Shan, LI Shuran, GUO Shanshan, WANG Daohan, CUI Xiaolan. Mechanisms of Gegen Tang granules against viral pneumonia in mice based on immune regulation [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 132-136. |
[3] | BAO Lei, GENG Zihan, LI Shuran, JI Zuen, ZHAO Ronghua, SUN Jing, GUO Shanshan, CUI Xiaolan. The critical role of TRP channels in the progression of viral pneumonia [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 137-140. |
[4] | JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166. |
[5] | LI Jiaxin, LIU Huimin, QIAN Wenxiu, MA Ning, SONG Lili, LI Yubo. Nephrotoxic effects and usage of traditional Chinese medicines based on the Traditional Chinese Medicine Systems Toxicology Database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 173-180. |
[6] | FAN Kaikai, WANG Cong, LIU Hongfeng, WANG Xiyong. Effects of clinical pharmacist interventions on usage of alanyl-glutamine injections in a hospital [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 181-184. |
[7] | ZHANG Jian, FANG Huihua. Applicability of evaluation standards for use of traditional Chinese medicine injections for promoting blood circulation and removing blood stasis [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 185-189. |
[8] | WANG Shan, XIE Bo, LIU Huimin, LI Zhihao. Adverse event signals for celecoxib based on FAERS database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 190-194. |
[9] | LI Yingfen, HAN Lei. Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198. |
[10] | XU Weijia, PENG Qi, HUANG Haiyu, ZHANG Leijiao, XIAO Hua, WU Xue. 285 cases of adverse drug reaction related to new antineoplastic drugs [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 199-203. |
[11] | GUO Qinghua, PENG Xiaoxiao, ZHU Ping, LIU Xilin, YANG Yinghua, CHEN Zhihai. One case of multiple organ dysfunction syndrome caused by amlodipine overdose [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 204-207. |
[12] | FANG Meilin, ZHENG Huimin, WANG Cunze, WANG Ling, RUAN Junshan. One case of generalized myalgia caused by oxaliplatin [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 208-210. |
[13] | LI Na, GUO Jun, GUO Wenjia, LYU Yinyin, LI Caihong, MU Xiangdong. One case of delayed skin allergic reaction caused by asthma treated with omalizumab injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 211-212. |
[14] | CAO Guiping, DENG Linlin, ZHU Ganhong, LU Ying, MA Shuang, CHEN Linlin, Liu Lili. One case of severe liver injury caused by Tianma Shouwu tablets [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 216-218. |
[15] | ZHU Ying, SHEN Lu, LI Lan, WU Jianmin, GAO Xiaojie. Adverse reaction monitoring of toothpaste in China under the new regulatory system [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 219-222. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||